Qiong Chen

1630 Dongfang Road
Pudong, 200127, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Reply by Authors.

Reply by Authors.

Journal: The Journal of urology

Published: March 18, 2025

Reply by Authors.

Reply by Authors.

Journal: The Journal of urology

Published: March 14, 2025

A Phase 2 Study of Tislelizumab as Neoadjuvant Treatment of Cisplatin-Ineligible High-Risk Upper Tract Urothelial Carcinoma.

A Phase 2 Study of Tislelizumab as Neoadjuvant Treatment of Cisplatin-Ineligible High-Risk Upper Tract Urothelial Carcinoma.

Journal: The Journal of urology

Published: February 25, 2025

EPO-Mimetic Peptide Pegmolesatide Therapy for Pure Red Cell Aplasia in a Patient with Non-dialysis-dependent Type 1 Diabetic Nephropathy: A Case Report.

EPO-Mimetic Peptide Pegmolesatide Therapy for Pure Red Cell Aplasia in a Patient with Non-dialysis-dependent Type 1 Diabetic Nephropathy: A Case Report.

Journal: Kidney medicine

Published: January 30, 2025

Clinical outcomes of immune checkpoint inhibitor plus nab-paclitaxel in metastatic upper tract urothelial carcinoma.

Clinical outcomes of immune checkpoint inhibitor plus nab-paclitaxel in metastatic upper tract urothelial carcinoma.

Journal: Translational andrology and urology

Published: July 22, 2023

CircPTEN suppresses human clear cell renal carcinoma progression and resistance to mTOR inhibitors by targeting epigenetic modification.

CircPTEN suppresses human clear cell renal carcinoma progression and resistance to mTOR inhibitors by targeting epigenetic modification.

Journal: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy

Published: March 22, 2023

CircRNA cRAPGEF5 inhibits the growth and metastasis of renal cell carcinoma via the miR-27a-3p/TXNIP pathway.

CircRNA cRAPGEF5 inhibits the growth and metastasis of renal cell carcinoma via the miR-27a-3p/TXNIP pathway.

Journal: Cancer letters

Published: August 23, 2019

DNA methylation-regulated QPCT promotes sunitinib resistance by increasing HRAS stability in renal cell carcinoma.

DNA methylation-regulated QPCT promotes sunitinib resistance by increasing HRAS stability in renal cell carcinoma.

Journal: Theranostics

Published: April 08, 2019

Specific expression of lncRNA RP13-650J16.1 and TCONS_00023979 in prostate cancer.

Specific expression of lncRNA RP13-650J16.1 and TCONS_00023979 in prostate cancer.

Journal: Bioscience reports

Published: November 21, 2017

Showing 1-9 of 9

Last Updated: 09/26/2026